Just in case we need to go through this again:
- GXY made $20,000,000 in profit in Q1, 2018.
- GXY has no debt, and $80,000,000 cash.
- GXY has three projects, one producing and two in development. They made $20million profit in three months from one project.
- Sal de Vida has the potential to generate total annual revenues in the region of US$215 million and operating cash flow before interest and tax of US$118 million per annum at full production rates.
- Canaccord Genuity, the Financial Times, and a range of others have predicted big things for GXY, with Canaccord setting a $4.50 target price.
- The potential for LPD's L-max tech to ramp up production is vast.
- Forums
- ASX - By Stock
- GXY
- Ann: Quarterly Report - March 2018
Ann: Quarterly Report - March 2018, page-176
-
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GXY (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online